Drug · CHEMBL709
ALFUZOSIN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. ALFUZOSIN. Drugs and targets, record CHEMBL709. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL709
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets3
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| ADRA1A | Adrenergic receptor alpha-1 | Adrenergic receptor alpha-1 agonist | AGONIST | https://conductscience.org/library/genes/148 |
| ADRA1B | Adrenergic receptor alpha-1 | Adrenergic receptor alpha-1 agonist | AGONIST | https://conductscience.org/library/genes/147 |
| ADRA1D | Adrenergic receptor alpha-1 | Adrenergic receptor alpha-1 agonist | AGONIST | https://conductscience.org/library/genes/146 |
Source ChEMBL
Diseases11
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| benign prostatic hyperplasia | Approval | ATC and TTD | 13 | 11 | https://conductscience.org/library/drugs?q=MONDO_0010811 |
| lower urinary tract symptom | Phase 3 | ClinicalTrials.gov | 5 | 5 | https://conductscience.org/library/drugs?q=EFO_0008008 |
| ureterolithiasis | Phase 3 | ClinicalTrials.gov | 5 | 5 | https://conductscience.org/library/drugs?q=MONDO_0007009 |
| Urinary retention | Phase 3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=HP_0000016 |
| erectile dysfunction | Phase 3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0005362 |
| nephrolithiasis | Phase 3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0008171 |
| chronic prostatitis | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0022103 |
| constipation disorder | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0002203 |
| hydronephrosis | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0005510 |
| multiple sclerosis symptom measurement | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=EFO_0803536 |
1 to 10 of 11Source Open Targets
See all 11 diseasesTrials37
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00103402 | Trial to Compare Alfuzosin Versus Placebo in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome | Phase 3 | 272 | 2020-06-12 | alfuzosin | Its name | ClinicalTrials.gov |
| NCT00696761 | The Long Term Effects of Alfuzosin(Xatral XL) in Lower Urinary Tract Symptoms(LUTS)/BPH Patients | Phase 4 | 232 | 2014-03-04 | alfuzosin | Its name | ClinicalTrials.gov |
| NCT00549939 | Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction | Phase 3 | 172 | 2011-02-08 | alfuzosin | Its name | ClinicalTrials.gov |
| NCT00893113 | An Efficacy Study to Evaluate Alfuzosin to Treat Men With Erectile Dysfunction and Mild Lower Urinary Tract Symptoms | Phase 3 | 74 | 2016-08-01 | alfuzosin | Its name | ClinicalTrials.gov |
| NCT01834729 | Effects of Alpha-1 Antagonist, Stress and Relaxation on Anorectal Functions | Phase 2 | 74 | 2019-01-11 | alfuzosin | Its name | ClinicalTrials.gov |
| NCT00576823 | Alfuzosin Treatment in Children and Adolescents With Hydronephrosis of Neuropathic Etiology | Phase 3 | 25 | 2011-02-08 | alfuzosin | Its name | ClinicalTrials.gov |
| NCT00029822 | Clinical Trial in Males With BPH (Enlarged Prostate) | Phase 3 | 1,522 | alfuzosin | Its name | ClinicalTrials.gov | |
| NCT00399464 | Efficacy and Safety of SL77.0499-10 (Alfuzosin) Versus Placebo and Tamsulosin in Japanese Patients With Benign Prostatic Hyperplasia | Phase 3 | 1,177 | alfuzosin | Its name | ClinicalTrials.gov | |
| NCT00290030 | ALFAURUS : A DB Randomized Parallel Group Study of Alfuzosin 10mg OD vs Placebo in the Management of AUR in Patients With a 1st Episode Due to BPH | Phase 3 | 800 | alfuzosin | Its name | ClinicalTrials.gov | |
| NCT00486785 | SAMBA: Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin | Phase 4 | 431 | alfuzosin | Its name | ClinicalTrials.gov |
1 to 10 of 37
See all 37 trialsComparisons in its trials5
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Alfuzosin vs Placebo: Number of Participants With Decline in Total Score ≥4 for the NIH-CPSI Total Score From Baseline to 12 Weeks | 68 of 138 | 66 of 134 | 272 | NCT00103402 | Trial comparisons |
| Alfuzosin vs Placebo: deaths from any cause | 0 of 138 | 0 of 134 | 272 | NCT00103402 | Trial comparisons |
| Alfuzosin vs Placebo: serious adverse events | 1 of 138 | 2 of 134 | 272 | NCT00103402 | Trial comparisons |
| Alfuzosin 0.1 mg/kg/Day vs Alfuzosin 0.2 mg/kg/Day: serious adverse events | 10 of 83 | 7 of 86 | 169 | NCT00549939 | Trial comparisons |
| Placebo, Then Alfuzosin vs Alfuzosin, Then Placebo: serious adverse events | 1 of 36 | 1 of 38 | 74 | NCT00893113 | Trial comparisons |
Papers from its trials4
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL709
GET https://conductscience.org/api/drugs/v1/CHEMBL709/trials?page=2